Policy usually moves through accumulated evidence. Occasionally a single case moves it faster than the evidence does, and the Charlotte Figi story is the clearest example in cannabis.
What Happened
Charlotte Figi was born in Colorado in 2006. She developed seizures in infancy and was eventually diagnosed with Dravet syndrome — a rare, severe, genetically-driven epilepsy that typically begins in the first year of life and responds poorly to conventional anticonvulsants.
By the time she was five, she was experiencing frequent and prolonged seizures, had lost skills she had previously acquired, and was on a combination of medications with significant side effects and limited benefit. Her family had worked through the standard treatment options.
They turned to a cannabis extract high in CBD and very low in THC — a profile deliberately chosen to avoid intoxication in a young child. The cultivar had been developed by growers in Colorado who had been working on high-CBD plants with little commercial interest at the time, since the market rewarded THC. It was subsequently renamed Charlotte’s Web.
Her family reported a substantial reduction in seizure frequency. The case was covered in a CNN documentary in 2013 by Sanjay Gupta, who used it as part of a public reversal of his own previous position on medical cannabis.
Charlotte died in April 2020, aged 13, following an illness during the early period of the COVID-19 pandemic.
What It Changed
The effect on policy was rapid and specific.
CBD-only laws spread quickly. A number of states that had shown no willingness to pass broad medical cannabis legislation passed narrow laws permitting high-CBD, low-THC preparations, usually for intractable epilepsy. These were limited laws — many were criticised as unworkable, with no legal supply mechanism attached — but they represented the first cannabis legislation in several conservative states.
The public conversation separated CBD from THC. Before this, cannabis was discussed largely as one thing. The case established in the public mind that the plant produces multiple compounds with different properties, and that a non-intoxicating one might have medical use. That distinction underpins the entire CBD market that followed.
Breeding priorities shifted. High-CBD cultivars went from a curiosity to a commercial category. See cannabis strains and the genetics behind them.
Research attention followed. Interest in CBD for epilepsy accelerated, and eventually produced randomised controlled trials supporting a purified CBD formulation for Lennox-Gastaut and Dravet syndromes — now the clearest example of a cannabis-derived medicine meeting the pharmaceutical evidence standard. See the science behind medical cannabis research.
Being Careful About What It Proves
It is worth being precise here, because the case is frequently used to support claims it does not establish.
A single case is not evidence of efficacy. Individual response can reflect the natural course of a condition, concurrent changes in treatment, or expectation effects. That is why controlled trials exist, and it is a general principle rather than scepticism about this case specifically.
What makes the story significant is not that it proved CBD works. It is that it prompted the research that subsequently did establish an effect, for a specific condition, with a specific formulation, at a specific dose. The formal evidence came afterwards.
The distinction matters because the case is routinely invoked to support CBD for conditions where no comparable evidence exists. Approval for two rare severe epilepsy syndromes is a narrow finding, and it does not extend across the retail CBD market.
What It Revealed About Product Consistency
This is the part most relevant to a testing laboratory, and it is usually left out.
The Figi family were administering an unregulated preparation to a child. Its composition depended on the growers producing it. There was no standardised dose, no batch-to-batch verification, and no regulatory framework covering any of it.
Families across the country who moved to Colorado to access similar products faced the same situation — and as demand grew, product quality across the emerging CBD market varied enormously. Independent analyses in the years that followed repeatedly found CBD content well off label claims, undisclosed THC, and contaminants including pesticides and heavy metals.
For a paediatric patient with a severe condition, an inaccurate dose is not a minor problem. If the CBD content of a batch varies by a factor of two, a dose that was working stops working, or produces effects nobody intended.
This is the practical legacy of the case for the testing sector. It made composition verification a mainstream concern rather than a technical one, and it is one of the reasons potency accuracy in cannabis products came to be treated as a safety issue rather than a labelling nicety. See potency testing and why third-party testing matters.
Where It Sits in the Larger Story
Cannabis policy in the United States moved slowly for decades and then quickly, and single cases carried disproportionate weight in that shift — partly because the research that would normally drive policy had been made difficult to conduct by the same laws under debate.
That is a poor way to make policy, and it was the mechanism available. The regulatory history is in from the Marihuana Tax Act to OMMA.
What the case ultimately demonstrated is that the question people care about is not whether cannabis has medical potential in the abstract. It is whether a specific product, at a specific composition, does something specific and reliable. Answering that requires measurement — which is the entire premise of cannabis lab testing.